Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 718 participants.
Also called NCT06236061
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 718 participants
- Sponsor
- Registry
-
NCT06236061
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT06236061. Randomized; triple masking; primary purpose treatment. Start 2024-04-08 (actual); primary completion 2025-05-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
- Condition
- Hypertension
- Intervention (Drug)
- LCZ
- Intervention (Drug)
- LCZ/AML 200 mg/2.5 mg
- Intervention (Drug)
- LCZ/AML 200 mg/5 mg
- Intervention (Drug)
- LCZ/AML 200 mg/10 mg
- Intervention (Other)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct06236061- Content hash
0dc9e88f931ac6caee118ecebac9e1e88b795d2a0adbaad811807ef9e135cdd4